TopFunds

Medpace

NASDAQ: MEDP

Stock price

612.33 USD

(+229.17%) 5 years

medical researchMedical - Diagnostics & ResearchInvestable Universe

Insider Transactions

5Y price score: 315
Help

The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.

A score of 100 indicates that the stock did as well as the S&P 500 Index.

A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.

5Y return: +229.17%
DATE RANGE:
USD PER SHARE

  • Stock price
  • Sales
  • Purchases
  • Stock awards

Transaction History

Trade log
DateActionSharesPriceShare ValueHoldingNameTitleSource
16-sep.-26Sale(8,770)621.3(5,448,713)515,153Troendle August J.director, 10 percent owner, officer: President & CEOlink
15-sep.-26Sale(15,971)620.8(9,915,436)523,923Troendle August J.director, 10 percent owner, officer: President & CEOlink
27-aug.-26Sale(650)620.3(403,176)539,894Troendle August J.director, 10 percent owner, officer: President & CEOlink
26-aug.-26Sale(3,858)617.8(2,383,511)955Kraft Robert O.directorlink
26-aug.-26Sale(4,000)620.0(2,480,120)540,544Troendle August J.director, 10 percent owner, officer: President & CEOlink
25-aug.-26Sale(673)620.4(417,516)544,544Troendle August J.director, 10 percent owner, officer: President & CEOlink
24-aug.-26Sale(1,983)620.2(1,229,916)545,217Troendle August J.director, 10 percent owner, officer: President & CEOlink
21-aug.-26Sale(13,995)624.5(8,739,178)547,200Troendle August J.director, 10 percent owner, officer: President & CEOlink
20-aug.-26Sale(3,400)625.2(2,125,816)12,830Brady Kevin M.officer: CFO & Treasurerlink
20-aug.-26Sale(27,174)618.8(16,814,999)561,195Troendle August J.director, 10 percent owner, officer: President & CEOlink

373.0

52-week range

677.9

612.33

Your model inputs

Required return / cost of capital
%
FCFF terminal growth rate
%

Your fair value & Margin of safety

To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.

Forecast:

Set price notification

Valuation

Free Cash Flow Yield

Help
FCF Yield TTM = Trailing Twelve Months free cash flow per share / current market price per shareLearn more

4.1 %

Dividend Yield TTM

-

Market cap $

$ 17,091

Price / Earnings TTM

Help
P/E TTM = current market price per share / Trailing Twelve Months diluted earnings per shareLearn more

35.9

Price / Book TTM

40

PEG TTM

Help
Price/Earnings-to-Growth ratio = P/E TTM divided by most recent annual diluted earnings per share growth rateLearn more

1.7

Earnings growth and return

LTM

5YR

10YR

Total return (price & dividends)

22 %

229.2 %

1,910.9 %

Free cash flow per share growth

1.7 %

283 %

1,052.6 %

Earnings per share growth

37.1 %

297.9 %

5,557.1 %

Analyst ratings

Price Target Low

515

Price Target High

692

Price Target Median

610

Buy

4

Hold

14

Sell

1

Financials

all figures in USD Millions except per share data

Periods:

View:

Forecast:

Help

Averages

based on historical growth rates (CAGR) and average margins for last 10 or max, available and up to 10 years.

Analysts

Average Revenue and Net Income forecast estimates from analysts who cover the stock.

Custom

you can edit default forecast based on averages or analysts consensus and use it to calculate fair value based on your assumptions.

ㅤ

Actual
10 year gagr
Estimated
Projected
Fiscal
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Average (A)
2026
2027
2028
2029
2030
Terminal
FISCAL PERIOD END DATES
SHOW FORECAST VS ACTUAL
01Earnings per share
Help
Diluted EPSLearn more
(0.3)
0.4
1
2
2.7
3.8
4.8
7.3
8.9
12.6
15.3
-
12.9
16.1
20.2
25.3
31.7
33.6
02FCF per share
2
2.2
2.1
3.8
4.9
6
6.2
10.4
12.5
17.9
23.1
27.7%
25.2
31.6
39.6
49.7
62.3
65.7
03Dividends per share
Help
Adjusted for splitsLearn more
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
04Dividends payout, %
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
05Revenue
$ 359.1
$ 421.6
$ 436.2
$ 704.6
$ 861
$ 925.9
$ 1,142
$ 1,460
$ 1,886
$ 2,109
$ 2,530
21.6%
$ 3,076
$ 3,739
$ 4,545
$ 5,525
$ 6,717
$ 6,918
06ㅤ% Change
-
17.4%
3.5%
61.6%
22.2%
7.5%
23.4%
27.8%
29.2%
11.8%
20%
21.6%
21.6%
21.6%
21.6%
21.6%
21.6%
21.6%
07Net Income
(8.7)
13.4
39.1
73.2
100.4
145.4
181.8
245.4
282.8
404.4
451.1
-
369.7
449.4
546.3
664.1
807.3
831.6
08ㅤ% Margin
(2.4)%
3.2%
9%
10.4%
11.7%
15.7%
15.9%
16.8%
15%
19.2%
17.8%
12% A
12%
12%
12%
12%
12%
12%
09CFO
85.9
91.7
97.4
156.6
201.9
258.7
263.3
388.1
433.4
608.8
713.2
23.6%
758.5
922.1
1,121
1,363
1,656
1,706
10ㅤ% Of revenue
23.9%
21.8%
22.3%
22.2%
23.5%
27.9%
23.1%
26.6%
23%
28.9%
28.2%
24.7% A
24.7%
24.7%
24.7%
24.7%
24.7%
24.7%
11CAPEX
(6.5)
(13.5)
(12.3)
(16)
(17.9)
(31.3)
(28.3)
(36.9)
(36.6)
(36.5)
(31.4)
17.1%
(36.7)
(43)
(50.4)
(59)
(69.1)
(80.9)
12ㅤ% Change
-
109.4%
(9.2)%
30.4%
11.8%
75%
(9.8)%
30.5%
(0.6)%
(0.3)%
(14.2)%
17.1% A
17.1%
17.1%
17.1%
17.1%
17.1%
17.1%
13FCFF
Help
Free Cash Flow to the Firm = Cash Flows from Operating Activities (09) – Capital Expenditures (11)Learn more
79.4
78.2
85.1
140.6
184
227.3
235.1
351.2
396.7
572.3
681.9
24%
721.8
879.1
1,071
1,304
1,587
1,625
14Total assets
984
979.1
950.7
967.9
1,143
1,391
1,660
1,353
1,657
2,101
1,976
7.2%
2,118
2,271
2,435
2,611
2,799
3,001
15ㅤ% Change
-
(0.5)%
(2.9)%
1.8%
18.1%
21.7%
19.4%
(18.5)%
22.5%
26.8%
(6)%
7.2%
7.2%
7.2%
7.2%
7.2%
7.2%
7.2%
16Total liabilities
570.6
368.4
447.2
378.2
416.8
584.9
707
966.1
1,098
1,275
1,516
10.3%
1,626
1,743
1,869
2,004
2,149
2,304
17ㅤ% Of assets
58%
37.6%
47%
39.1%
36.5%
42.1%
42.6%
71.4%
66.3%
60.7%
76.8%
76.8% A
76.8%
76.8%
76.8%
76.8%
76.8%
76.8%
18Shareholders Equity
413.5
610.7
503.5
589.7
726.3
805.8
952.9
386.4
559
825.5
459.1
1.1%
492.2
527.7
565.8
606.7
650.4
697.4
19Net Debt
363.1
126.5
195.1
56.4
(86.7)
(162.6)
(330.3)
160.6
(103.3)
(519.9)
(246.6)
-
-
-
-
-
-
-
20Shares Outstanding
Help
Diluted Weighted-average Shares OutstandingLearn more
39,631
36,329
39,839
36,912
37,576
37,708
37,697
33,671
31,841
32,014
29,527
(2.9)%
28,671
27,839
27,032
26,248
25,487
24,747
21ㅤ% Change
-
(8.3)%
9.7%
(7.4)%
1.8%
0.4%
(0)%
(10.7)%
(5.4)%
0.5%
(7.8)%
(2.9)%
(2.9)%
(2.9)%
(2.9)%
(2.9)%
(2.9)%
(2.9)%
22ROA
(0.9)%
1.4%
4.1%
7.6%
8.8%
10.5%
11%
18.1%
17.1%
19.3%
22.8%
-
17.5%
19.8%
22.4%
25.4%
28.8%
27.7%
23ROE
(2.1)%
2.2%
7.8%
12.4%
13.8%
18%
19.1%
63.5%
50.6%
49%
98.3%
-
75.1%
85.2%
96.6%
109.5%
124.1%
119.2%
24Interest coverage
0.8
2.7
8.6
12.4
81.2
-
1,891.6
95.9
690.2
-
-
-
-
-
-
-
-
-
25Dividend Yield
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
26P/E Ratio
(99.2)
94.9
36.3
25.8
30.1
34.2
43
28.1
33.3
25.4
35.9
-
-
-
-
-
-
-
27Stock price range
-
27-38
22-38
32-64
49-86
62-149
132-228
130-227
174-313
285-457
277-618
-
-
-
-
-
-
-
28Market Cap
Help
End of Period Market CapLearn more
1,101
1,287
1,416
1,882
3,016
4,960
7,805
6,880
9,417
10,285
16,201
30.9%
18,726
20,574
22,607
24,843
27,303
-
29FCF Yield
7.2%
6.1%
6%
7.5%
6.1%
4.6%
3%
5.1%
4.2%
5.6%
4.2%
(5.2)%
3.9%
4.3%
4.7%
5.3%
5.8%
-
30Average stock price
-
32.5
30.2
48
67.6
105.5
180
178.4
243.5
371.1
447.9
33.8%
653.1
739
836.3
946.5
1,071.3
-
31 CEO
AM
Dr. August James Troendle M.D.
AT
August James Troendle